Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Hematology
How do you approach a patient with CMML requiring platelet transfusions?
Would you consider use of TPO-R agonists such as eltrombopag or romiplostim for a patient like this?
Related Questions
How do you manage a patient with low risk MDS who achieves transfusion independence with luspatercept but continues to have fatigue?
Would you hold off iron chelation in a transfusion dependent MDS patient with elevated ferritin but with negative iron stain on the bone marrow?
What is your approach for choosing between Imetelstat and Luspatercept in managing MDS related anemia?
How do you approach management for CCUS with severe cytopenias?
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?
Would you consider TPO agonists for thrombocytopenia from low risk MDS?
For patients with newly diagnosed AML who are induction chemotherapy eligible, do you dose reduce cytarabine for any mild elevation in AST/ALT?
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
What are your top takeaways in Hematologic Malignancies from ASH 2024?